EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are now the standard treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring activating mutations in the EGFR gene [1–3].